what is Abecma (By AI)

 Abecma (generic name: idecabtagene vicleucel) is a CAR T-cell therapy used to treat certain types of blood cancer, specifically:

Approved Use

  • Relapsed or refractory multiple myeloma in adult patients who have received at least four prior lines of therapy, including:

    • An immunomodulatory agent (e.g., lenalidomide),

    • A proteasome inhibitor (e.g., bortezomib),

    • An anti-CD38 monoclonal antibody (e.g., daratumumab).

How It Works

Abecma is a personalized gene therapy. It involves:

  1. Collecting T cells from the patient's blood.

  2. Genetically modifying them in a lab to express a chimeric antigen receptor (CAR) that targets BCMA (B-cell maturation antigen) — a protein highly expressed on multiple myeloma cells.

  3. Reinfusing the modified T cells into the patient to seek out and destroy cancer cells.

Manufacturer

  • Co-developed by Bristol Myers Squibb and bluebird bio.

Approval

  • Approved by the FDA in March 2021, the first CAR T-cell therapy specifically for multiple myeloma.

Side Effects

  • Common: Fatigue, cytokine release syndrome (CRS), infections, low blood counts, neurotoxicity.

  • Serious side effects can be life-threatening, requiring hospitalization and intensive monitoring.

تعليقات

المشاركات الشائعة من هذه المدونة

Tips on how to write a meta-analysis by Dr. Nehad Jaser

Centers for Disease Control and Prevention (CDC) categorizes germs into three main categories

The history of herbal medicine